Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Burkitt Lymphoma 12Prostatic Neoplasms 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Large B-Cell, Diffuse 4Plasmablastic Lymphoma 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Follicular 2Immunoblastic Lymphadenopathy 2Enteropathy-Associated T-Cell Lymphoma 2Neuroblastoma 1Myelodysplastic Syndromes 1Multiple Myeloma 1Melanoma 1Lymphoma, Primary Effusion 1Lymphoma, B-Cell 1Lymphoma, AIDS-Related 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Hormone-Resistant Prostate Cancer 1Hodgkin Disease 1Hematologic Neoplasms 1HIV Infections 1Composite Lymphoma 1Carcinoma, Merkel Cell 1Carcinoma, Basal Cell 1Blast Crisis 1

Interventions

Etoposide 3Cyclophosphamide 3Vincristine 2Rituximab 2Prednisone 2Doxorubicin 2varlilumab 1prednylidene 1liposomal doxorubicin 1etoposide phosphate 1deltacortene 1Vorinostat 1Ultrasonography 1Peripheral Blood Stem Cell Transplantation 1Nivolumab 1Lenalidomide 1Immunoglobulin G 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Endoscopy 1Electrocardiography 1Echocardiography 1Disulfides 1Cytarabine 1Carmustine 1CT-P10 1Bronchoscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lymphoma, Primary Effusion × deltacortene × Clear all
NCT01193842 2023-11-21

Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas

National Cancer Institute (NCI)

Phase 1/2 Completed
107 enrolled 24 charts
Lymphoid

Plasmablastic Lymphoma, Lymphoma, Follicular, HIV Infections, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Primary Effusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡